珀金埃尔默推出Vectra® Polaris™ 自动定量病理成像系统

PerkinElmer Launches Vectra® Polaris™ Automated Quantitative Pathology Imaging System

New Platform Helps Research Immuno-oncologists and Pathologists Accelerate the Study of Cancer

WALTHAM, Mass. – January 26, 2017– PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its Vectra® Polaris™ Automated Quantitative Pathology Imaging System. This new multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.

The Vectra Polaris system integrates high throughput, seven-color multispectral imaging with whole-slide scanning in a simplified digital pathology workflow to support the quantification and analysis of tissue sections that are stained with multiple immunohistochemical stains. This helps scientists assess biomarkers that probe deeper into the biology occurring in the immune system and cancer by detecting multiple cell types and their functional states, while also allowing researchers to determine their spatial distributions.

“From basic research to clinical research studies, scientists continue to seek advanced imaging technologies to better analyze and understand disease mechanisms,” said Jim Corbett, Executive Vice President and President, Discovery & Analytical Solutions, PerkinElmer. “The Vectra Polaris system is an innovative solution that helps further the exploration of new cancer immunotherapy approaches to help unlock the promise of precision medicine.”

The Vectra Polaris system is part of PerkinElmer's Phenoptics™ workflow solution for quantitative pathology research, which enables exploration of the interaction between tumors and immune cells to obtain a deeper understanding of disease mechanisms.

“PerkinElmer's multiplex IHC platform has addressed a critical need in immuno-oncology research to reveal the cell-level biology occurring in the tumor and its microenvironment that drives disease progression and response to immunotherapy,” said Dr. Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center (Oregon). “The development of the Vectra Polaris system has come at the right time, to support the transition from an exploratory research tool to a high throughput rugged high speed slide analysis research system that overlays PerkinElmer's unique multispectral technology on to a digital pathology workflow. I believe the Vectra technology will become the standard for tissue biomarker studies in immuno-oncology research and form the basis for tailoring cancer therapies of the future. '

For more information on the Vectra Polaris system, please visit www.perkinelmer.com/vectrapolaris

For more information on PerkinElmer’s Phenoptics solutions, please visit www.perkinelmer.com/cancer-immunology

About PerkinElmer

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE or at www.perkinelmer.com.

Follow us on Twitter @PKILifeScience.

珀金埃尔默推出Vectra® Polaris™ 自动定量病理成像系统

新的平台，有助于研究免疫肿瘤学家和病理学家加速癌症的研究

WALTHAM，Mass。2017年1月26日––PerkinElmer，Inc.，一家全球领先的致力于一个更健康的世界创新，今天宣布其Vectra® Polaris™ 自动定量病理成像系统。这种新的多模态组织成像系统，使研究人员获得更深层次的理解与新的癌症免疫治疗方法的疾病机制。

Vectra® Polaris™ 系统集成了高吞吐量，整个幻灯片扫描在一个简化的数字病理工作流支持的组织切片，免疫组化染色多量化分析七彩色多光谱成像。这有助于科学家通过探测多种细胞类型及其功能状态来评估生物标志物在免疫系统和癌症中的深入发现，同时也允许研究人员确定其空间分布。

“从基础研究到临床研究，科学家们不断寻求先进的成像技术来更好地分析和理解疾病的机制，”珀金埃尔默发现和分析解决方案执行副总裁和总裁Jim Corbett说，“Vectra® Polaris™ 系统是一个创新的解决方案，推动新的癌症免疫治疗的方法，为精准医学的探索提供保证。”

Vectra® Polaris™ 系统是PerkinElmer的phenoptics™工作流解决方案定量病理学研究的一部分，从而使肿瘤获得疾病发病机制的深入了解免疫细胞间的相互作用的探索。

“PerkinElmer的多重免疫组化平台已经解决的一个关键需要在肿瘤免疫研究揭示细胞水平的生物学发生在肿瘤及其微环境，促使疾病进展和免疫反应，”Bernard A. Fox博士说，博士，主任，分子生物学和肿瘤免疫学实验室，罗伯特·W·弗兰兹癌症研究中心在Earle A. Chiles研究院在普罗维登斯癌症中心（俄勒冈）。“威达北极星系统的发展已经在正确的时间来临，支持从一个探索性的研究工具，高吞吐量的崎岖的高速滑动分析研究系统涵盖了PerkinElmer的独特的多光谱技术在数字病理工作流程的转变。我相信，该技术将成为肿瘤免疫研究组织生物标志物研究的标准和形式设计未来的癌症治疗的基础。”

在Vectra® Polaris™ 系统的更多信息，请访问www.perkinelmer.com/vectrapolaris

在phenoptics PerkinElmer的解决方案的更多信息，请访问www.perkinelmer.com/cancer-immunology

有关珀金埃尔默公司
珀金埃尔默公司是一家致力于为创建更为健康的世界而不懈努力、锐意创新的公司，也是无机光谱分析仪器领域的领导者。2015年度企业营业额达23亿美元，在全球150多个国家拥有8000多名员工，为标准普尔500指数中的一员，纽交所上市代号1-877-PKI-NYSE。了解更多有关珀金埃尔默公司的信息，请访问www.perkinelmer.com